Toxic Nephropathy: Uric Acid, Rhabdomyolysis, and Tumor Lysis Syndrome

  • Timothy E. BunchmanEmail author


In this chapter we will discuss the relative risk of toxic (pigment) nephropathy in certain disease states. We will discuss the specific complication associated with uric acid, rhabdomyolysis, as well as that associated with tumor lysis syndrome. This section will also discuss the relative approaches to prevention and intervention if necessary.


  1. 1.
    Tsuji T, Ohishi K, Takeda A, et al. The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia. Clin Exp Neprhol. 2018. Scholar
  2. 2.
    Xu X, Hu J, Song N, et al. Hyperuricemia increases the risk of acute kidney injury: a systematic review and meta-analysis. BMC Nephrol. 2017;18:27.CrossRefGoogle Scholar
  3. 3.
    Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97:2998–3003.CrossRefGoogle Scholar
  4. 4.
    Hobbs DJ, Steinke J, Chung J, et al. Rasburicase improves hyperuricemia in infants with acute kidney injury. Pediatr Nephrol. 2010;25:305–9.CrossRefGoogle Scholar
  5. 5.
    Feig DI. Serum uric acid and the risk of hypertension and chronic kidney disease. Curr Opin Rheumatol. 2014;26(2):176–85.CrossRefGoogle Scholar
  6. 6.
    Al-Ismaili Z, Piccioni M, Zappitelli M. Rhabdomyolysis: pathogenesis of renal injury and management. Pediatr Nephrol. 2011;26:1781–8.CrossRefGoogle Scholar
  7. 7.
    Mannix R, Tan ML, Wright R, et al. Acute pediatric rhabdomyolysis: cause and rates of renal failure. Pediatrics. 2006;118:2119–25.CrossRefGoogle Scholar
  8. 8.
    Eneas JF, Schoenfeld PY, Humphreys MH. The effect of infusion of mannitol-sodium bicarbonate on the clinical course of myoglobinuria. Arch Intern Med. 1979;139:801–5.CrossRefGoogle Scholar
  9. 9.
    Naka T, Jones D, Baldwin I, et al. Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: a case report. Crit Care. 2005;9:R90–5.CrossRefGoogle Scholar
  10. 10.
    Prusakowski MK, Cannone D. Pediatric oncologic emergencies. Hematol Oncol Clin N Am. 2017;31:959–80.CrossRefGoogle Scholar
  11. 11.
    Nguyen T, Ondrik D, Zhufyak O, et al. Hyperkalemia and potential pitfalls of sodium polystyrene sulfonate. JAAPA. 2015;28(3):41–5.CrossRefGoogle Scholar
  12. 12.
    Bakir AA. The fatal interplay of aluminum and citrate in chronic renal failure: a lesson from three decades ago. Artif Organs. 2015;39(2):87–9.CrossRefGoogle Scholar
  13. 13.
    Sinha R, Sethi SK, Bunchman T, et al. Prolonged intermittent renal replacement therapy in children. Pediatr Nephrol. 2018;33(8):1283–96.CrossRefGoogle Scholar
  14. 14.
    Sakarcan A, Quigley R. Hyperphosphatemia in tumor lysis syndrome: the role of hemodialysis and continuous veno-venous hemofiltration. Pediatr Nephrol. 1994;8(3):351–3.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Children’s Hospital of Richmond at Virginia Commonwealth UniversityRichmondUSA

Personalised recommendations